Canada Pension Plan Investment Board’s Intellia Therapeutics NTLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$129K Sell
10,100
-30,300
-75% -$386K ﹤0.01% 1628
2025
Q4
$363K Buy
+40,400
New +$556K ﹤0.01% 1434
2023
Q2
Sell
-20,100
Closed -$749K 1067
2023
Q1
$749K Buy
20,100
+16,771
+504% +$658K ﹤0.01% 936
2022
Q4
$116K Sell
3,329
-1,000
-23% -$47.5K ﹤0.01% 1014
2022
Q3
$242K Buy
4,329
+800
+23% +$49.6K ﹤0.01% 1019
2022
Q2
$183K Sell
3,529
-700
-17% -$35.5K ﹤0.01% 1089
2022
Q1
$307K Buy
+4,229
New +$358K ﹤0.01% 1025
2021
Q4
Sell
-14,000
Closed -$1.88M 1566
2021
Q3
$1.88M Buy
+14,000
New +$2.12M ﹤0.01% 857

Other funds holding NTLA

Canada Pension Plan Investment Board's NTLA Position: Q1 2026 in Review

Canada Pension Plan Investment Board reduced its Intellia Therapeutics (NTLA) stake by 75% in Q1 2026, selling an estimated $386K and leaving 10,100 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1628.

Canada Pension Plan Investment Board first reported a position in NTLA in Q3 2021 and has held it in 8 quarters since. The position peaked at $1.88M in Q3 2021. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Canada Pension Plan Investment Board held 10,100 shares of Intellia Therapeutics worth $129K as of Q1 2026.
  • Canada Pension Plan Investment Board sold 30,300 Intellia Therapeutics shares in Q1 2026, an estimated $386K.
  • Intellia Therapeutics made up ﹤0.01% of Canada Pension Plan Investment Board's portfolio in Q1 2026, its #1628 holding.
  • Canada Pension Plan Investment Board first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 8 quarters since.
  • Canada Pension Plan Investment Board's Intellia Therapeutics position peaked at $1.88M in Q3 2021.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Canada Pension Plan Investment Board's 13F filing for Q1 2026, filed 15 May 2026.